- Home
- GALT vs IDYA Comparison
GALT vs IDYA Comparison
Compare GALT & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GALT
- IDYA
- Stock Information
- Founded
- GALT 2000
- IDYA 2015
- Country
- GALT United States
- IDYA United States
- Employees
- GALT N/A
- IDYA N/A
- Industry
- GALT Biotechnology: Pharmaceutical Preparations
- IDYA Biotechnology: Pharmaceutical Preparations
- Sector
- GALT Health Care
- IDYA Health Care
- Exchange
- GALT Nasdaq
- IDYA Nasdaq
- Market Cap
- GALT 147.8M
- IDYA 2.2B
- IPO Year
- GALT N/A
- IDYA 2019
- Fundamental
- Price
- GALT $1.04
- IDYA $26.23
- Analyst Decision
- GALT Strong Buy
- IDYA Strong Buy
- Analyst Count
- GALT 1
- IDYA 12
- Target Price
- GALT $11.00
- IDYA $53.67
- AVG Volume (30 Days)
- GALT 1.1M
- IDYA 1.0M
- Earning Date
- GALT 11-13-2024
- IDYA 11-04-2024
- Dividend Yield
- GALT N/A
- IDYA N/A
- EPS Growth
- GALT N/A
- IDYA N/A
- EPS
- GALT N/A
- IDYA N/A
- Revenue
- GALT N/A
- IDYA $3,922,000.00
- Revenue This Year
- GALT N/A
- IDYA N/A
- Revenue Next Year
- GALT N/A
- IDYA $251.89
- P/E Ratio
- GALT N/A
- IDYA N/A
- Revenue Growth
- GALT N/A
- IDYA N/A
- 52 Week Low
- GALT $0.73
- IDYA $24.48
- 52 Week High
- GALT $4.27
- IDYA $47.74
- Technical
- Relative Strength Index (RSI)
- GALT 20.80
- IDYA 37.58
- Support Level
- GALT $1.80
- IDYA $24.48
- Resistance Level
- GALT $2.36
- IDYA $27.15
- Average True Range (ATR)
- GALT 0.27
- IDYA 1.34
- MACD
- GALT -0.08
- IDYA -0.11
- Stochastic Oscillator
- GALT 15.07
- IDYA 7.90
About GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About IDYA IDEAYA Biosciences Inc.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. It is engaged in applying capabilities across multiple classes of precision medicine, including direct targeting of oncogenic pathways and synthetic lethality. The company's product candidate IDE196 is a protein kinase C, or PKC, an inhibitor for genetically defined cancers having GNAQ or GNA11 gene mutations.